The object of this application is the synthesis of analogues and homologues of trimethoprim (TMP) and its P. carinii dihydrofolate reductase (DHFR) selective analogue epiroprim as potent and selective inhibitors of DHFR from P. carinii (pc), T. gondii (tg) and M. avium (ma) and as potential clinical candidates for the treatment of often fatal infections caused by these organisms in patients with acquired immunodeficiency syndrome (AIDS). The target compounds were designed using molecular modeling based on the X-ray crystal structure of TMP and piritrexim (PTX) with P. carinii DHFR and as hybrid molecules of TMP and epiroprim [which are selective but poor inhibitors of DHFR and trimetrexate (TMQ)] and PTX (which are potent but nonselective inhibitors of DHFR), in an attempt to preserve both selectivity and potency in single drug entities for pcDHFR, tgDHFR and/or maDHFR. Compounds recently synthesized in the P.I.'s laboratory support this hypothesis. The compound syntheses are proposed via suitable modifications of procedures carried out by the P.I. and via established literature methods. Initially, two analogues of each series (total of 18 compounds) will be synthesized and evaluated as inhibitors of pcDHFR, tgDHFR, and maDHFR, with rat liver (rl)DHFR and human (h)DHFR serving as mammalian reference enzymes to determine selectivity. Depending upon the biological results of these initial analogues other compounds in the same series will be synthesized or not synthesized. Thus, the biological activity obtained will drive the synthetic targets. Based on the enzyme inhibitory studies, selected analogues will be evaluated against P. carinii and T. gondii cells in culture and against human cells for cytotoxicity and subsequently in whole animal (murine) models of P. carinii and T. gondii. These biological evaluations will be carried out on a collaborative basis. In addition, X-ray crystal structures of selected analogues with DHFRs will be determined on a collaborative basis. The results of this study will provide a molecular basis for selectivity and potency in single drug entities as it pertains to DHFR binding to pcDHFR, tgDHFR, and maDHFR. Further, these compounds may provide selective, less toxic, clinically useful agents against P. carinii, T. gondii, and M. avium infections in AIDS patients. Selected analogues will also be submitted to the in vitro preclinical tumor cell culture program of the National Cancer Institute.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI041743-02
Application #
2673077
Study Section
AIDS and Related Research Study Section 4 (ARRD)
Project Start
1997-04-01
Project End
2000-03-31
Budget Start
1998-04-01
Budget End
1999-03-31
Support Year
2
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Duquesne University
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
004501193
City
Pittsburgh
State
PA
Country
United States
Zip Code
15282
Zaware, Nilesh; Kisliuk, Roy; Bastian, Anja et al. (2017) Synthesis and evaluation of 5-(arylthio)-9H-pyrimido[4,5-b]indole-2,4-diamines as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents. Bioorg Med Chem Lett 27:1602-1607
Gangjee, Aleem; Jain, Hiteshkumar D; Phan, Jaclyn et al. (2010) 2,4-Diamino-5-methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors. Bioorg Med Chem 18:953-61
Gangjee, Aleem; Adair, Ona O; Pagley, Michelle et al. (2008) N9-substituted 2,4-diaminoquinazolines: synthesis and biological evaluation of lipophilic inhibitors of pneumocystis carinii and toxoplasma gondii dihydrofolate reductase. J Med Chem 51:6195-200
Gangjee, Aleem; Jain, Hiteshkumar D; Queener, Sherry F et al. (2008) The effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents. J Med Chem 51:4589-600
Gangjee, Aleem; Lin, Xin; Kisliuk, Roy L et al. (2005) Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofol J Med Chem 48:7215-22
Gangjee, Aleem; Lin, Xin; Queener, Sherry F (2004) Design, synthesis, and biological evaluation of 2,4-diamino-5-methyl-6-substituted-pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors. J Med Chem 47:3689-92
Gangjee, Aleem; Adair, Ona O; Queener, Sherry F (2003) Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents. J Med Chem 46:5074-82
Cody, Vivian; Galitsky, Nikolai; Luft, Joseph R et al. (2003) Analysis of two polymorphic forms of a pyrido[2,3-d]pyrimidine N9-C10 reversed-bridge antifolate binary complex with human dihydrofolate reductase. Acta Crystallogr D Biol Crystallogr 59:654-61
Cody, Vivian; Luft, Joseph R; Pangborn, Walter et al. (2003) Analysis of three crystal structure determinations of a 5-methyl-6-N-methylanilino pyridopyrimidine antifolate complex with human dihydrofolate reductase. Acta Crystallogr D Biol Crystallogr 59:1603-9
Gangjee, Aleem; Zeng, Yibin; McGuire, John J et al. (2002) Synthesis of N-[4-[1-ethyl-2-(2,4-diaminofuro[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid as an antifolate. J Med Chem 45:1942-8

Showing the most recent 10 out of 20 publications